| Assessment Status | Rapid Review Complete |
| HTA ID | 26051 |
| Drug | Afamelanotide |
| Brand | Scenesse® |
| Indication | Afamelanotide (Scenesse®) is indicated for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria. |
| Assessment Process | |
| Rapid review commissioned | 25/09/2026 |
| Rapid review completed | 15/10/2026 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of afamelanotide (Scenesse®) for this indication compared with the current standard of care. |